학술논문

Predominance of weakly cytotoxic, T-betLowEomesNeg CD8+ T-cells in human gastrointestinal mucosa: implications for HIV infection
Document Type
article
Source
Mucosal Immunology. 10(4)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Clinical Research
Vaccine Related
Infectious Diseases
Immunization
HIV/AIDS
Aetiology
2.1 Biological and endogenous factors
Infection
Good Health and Well Being
AIDS Vaccines
Anti-Retroviral Agents
CD8-Positive T-Lymphocytes
Cells
Cultured
Cellular Microenvironment
Cytotoxicity
Immunologic
Female
Granzymes
HIV Infections
Humans
Intestinal Mucosa
Male
Perforin
Rectum
T-Box Domain Proteins
Transforming Growth Factor beta
Biological Sciences
Medical and Health Sciences
Language
Abstract
The gastrointestinal mucosa is an important site of HIV acquisition, viral replication, and pathogenesis. Immune cells in mucosal tissues frequently differ in phenotype and function from their non-mucosal counterparts. Although perforin-mediated cytotoxicity as measured in blood is a recognized correlate of HIV immune control, its role in gastrointestinal tissues is unknown. We sought to elucidate the cytotoxic features of rectal mucosal CD8+ T-cells in HIV infected and uninfected subjects. Perforin expression and lytic capacity were significantly reduced in rectal CD8+ T-cells compared with their blood counterparts, regardless of HIV clinical status; granzyme B (GrzB) was reduced to a lesser extent. Mucosal perforin and GrzB expression were higher in participants not on antiretroviral therapy compared with those on therapy and controls. Reduction in perforin and GrzB was not explained by differences in memory/effector subsets. Expression of T-bet and Eomesodermin was significantly lower in gut CD8+ T-cells compared with blood, and in vitro neutralization of TGF-β partially restored perforin expression in gut CD8+ T-cells. These findings suggest that rectal CD8+ T-cells are primarily non-cytotoxic, and phenotypically shaped by the tissue microenvironment. Further elucidation of rectal immune responses to HIV will inform the development of vaccines and immunotherapies targeted to mucosal tissues.